<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Aminosalicylic Acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00233</strong>&#160; (APRD00749, EXPT00693)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00233/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00233/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00233.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00233.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00233.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00233.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00233.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00233">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>4-aminosalicylate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>4-aminosalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>p-aminosalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>para-amino salicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>para-aminosalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>PAS</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Aminosalicylate Sodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000354/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000354/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: FVVDKUPCWXUVNP-UHFFFAOYSA-M</li>
              <li>Monoisotopic Mass: 175.024537738</li>
              <li>Average Mass: 175.1172</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000354">DBSALT000354</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Pamisyl</td><td>Parke-Davis</td></tr><tr><td>Paser</td><td>Parke-Davis</td></tr><tr><td>Rexipas</td><td>Bristol-Myers Squibb</td></tr><tr><td>Rezipas</td><td>Bristol-Myers Squibb</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antitubercular-agents">Antitubercular Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>65-49-6</td></tr><tr><th>Weight</th><td>Average: 153.1354<br>Monoisotopic: 153.042593095</td></tr><tr><th>Chemical Formula</th><td>C<sub>7</sub>H<sub>7</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>WUBBRNOQWQTFEX-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-amino-2-hydroxybenzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=CC(O)=C(C=C1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00233.gif?1265922774">show</a>(9.18 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzoic Acid and Derivatives</td></tr><tr><th>Direct parent</th><td>Aminobenzoic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Salicylic Acids; Benzoic Acids; Benzoyl Derivatives; Aminophenols; Anilines; Primary Aromatic Amines; Polyols; Enols; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>aminophenol; benzoyl; phenol derivative; aniline; primary aromatic amine; polyol; polyamine; carboxylic acid derivative; enol; carboxylic acid; enolate; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminobenzoic acid derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of tuberculosis</td></tr><tr><th>Pharmacodynamics</th><td>Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs (most often isoniazid) for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The two major considerations in the clinical pharmacology of aminosalicylic acid are the prompt production of a toxic inactive metabolite under acid conditions and the short serum half life of one hour for the free drug. Aminosalicylic acid is bacteriostatic against <i>Mycobacterium tuberculosis</i> (prevents the multiplying of bacteria without destroying them). It also inhibits the onset of bacterial resistance to streptomycin and isoniazid.</td></tr><tr><th>Mechanism of action</th><td>There are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against <i>Mycobacterium tuberculosis</i>. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The binding of para-aminobenzoic acid to pteridine synthetase acts as the first step in folic acid synthesis. Aminosalicylic acid binds pteridine synthetase with greater affinity than para-aminobenzoic acid, effectively inhibiting the synthesis of folic acid. As bacteria are unable to use external sources of folic acid, cell growth and multiplication slows. Secondly, aminosalicylic acid may inhibit the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by <i>M. tuberculosis</i>.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>50-60%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=4 gm/kg (orally in mice); LD<sub>50</sub>=3650 mg/kg (orally in rabbits)</td></tr><tr><th>Affected organisms</th><td><ul><li>Mycobacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9356</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.7101</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.852</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8405</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9777</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9905</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9337</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8174</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8358</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7782</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8645</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8281</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9627</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5778</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7324</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9157</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9388
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8045
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6246
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.5761 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9689
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9676
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Century pharmaceuticals inc</li>
<li>Hexcel chemical products</li>
<li>Panray corp sub ormont drug and chemical co inc</li>
<li>Lannett co inc</li>
<li>Consolidated midland corp</li>
<li>Jacobus pharmaceutical co</li>
<li>Bristol myers squibb co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Jacobus Pharmaceutical Co.</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Granule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00993">Azathioprine</a></td><td>Aminosalicylic acid may increase the toxicity of thiopurine, azathioprine.</td></tr><tr><td><a href="/drugs/DB01033">Mercaptopurine</a></td><td>Aminosalicylic acid may increase the toxicity of thiopurine, mercaptopurine.</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>Risk of additive toxicity (e.g. bleed risk). Aminosalicylic acid may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Increased risk of gastrointestinal bleeding. </td></tr><tr><td><a href="/drugs/DB00352">Tioguanine</a></td><td>Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>